Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

to $1.00 per share which may be paid upon the achievement of certain regulatory and commercial milestones. The first CVR payment of $0.50 per share (or $87.5 million) would become payable when either (i) Cinryze is approved by the FDA for acute treatment of HAE and the FDA grants orphan exclusivity for Cinryze encompassing the acute treatment of HAE to the exclusion of all other human C1 inhibitor products or, (ii) orphan exclusivity for the acute treatment of HAE has not become effective for any third party's human C1 inhibitor product by October 21, 2010. The second CVR payment of $0.50 per share ($87.5 million) would become payable when Cinryze reaches at least $600 million in cumulative net product sales within 10 years of closing of the acquisition.

Looking ahead in 2009

ViroPharma is providing guidance for the year 2009 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2009, ViroPharma expects the following

  • Net product sales are expected to be $250 to $270 million. This guidance assumes no generic versions of Vancocin are approved in 2009 and excludes any revenue guidance for Cinryze.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses, including the impact of SFAS 123R, are expected to be $130 to $145 million, which includes approximately $25 million of expenses and previous commitments related to maribavir. SFAS 123R expenses are expected to be between $11 and $13 million.

Conference Call and Webca
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 The report "Chocolate, Cocoa ... Trade, Prices, Geography Trend and Forecast (2011 - 2016)," ... and geography and studies the major market drivers, restraints, ... Europe, and Asia. , The global chocolate market is ... billion in 2016 at an estimated CAGR of 2.7% ...
(Date:10/19/2014)... According to market research report “Outdoor Wi-Fi Market ... Global Advancements, Forecasts and Analysis (2013 - 2018)", ... with analysis and forecasting of the global revenues. ... and the restrains for this market with the ... Browse 65 market data tables and 69 figures ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The ... - Trends and Forecasts to 2019", analyzes the ... in order to understand the industry details such ... opportunities across various geographic regions. , Browse 81 ... 202 Slides and in-depth TOC on “1,6-Hexanediol Market ...
(Date:10/18/2014)... The Asia-Pacific Liquid Crystal on Silicon (LCoS) display ... Asia-Pacific with analysis and forecast of revenue. This market ... expected to reach $380.0 million by 2018, at a ... through the TOC of the Asia-Pacific LCoS display market ... provided. This also provides a glimpse of the segmentation ...
Breaking Biology Technology:Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3
... ... HPCwire,s Readers, Choice Award for Best Application of Green Computing. The award was ... ongoing in Portland, Ore. , ... Portland, OR (Vocus) Nov. 17, 2009 --- The U.S. Department of Energy,s ...
... Pharma guarantees to purchase 50,000 KINLYTIC vials over next ... Biosystems Inc. (MBX:TSX), a biotech company focused on virology ... agreement with Riso Pharma that guarantees purchases of not ... years. KINLYTIC (Urokinase) is Microbix, thrombolytic agent for treating ...
... , ROCKVILLE, Md., Nov. 17 Neuralstem, Inc. (NYSE Amex: ... the third quarter ended September 30, 2009. , (Logo: ... of 2009, the Company reported a net loss of $5,096,983, or ... $0.10 per share, for the comparable 2008 period. The increase was ...
Cached Biology Technology:Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 2Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 3Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 4Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region 2Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 2Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 5Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 6Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 7
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
(Date:10/14/2014)... 14, 2014 – High doses of fish oil supplements, rich ... common type of irregular heartbeat in which the heart can ... of the AFFORD trial led by the Montreal Heart Institute ... of Cardiology on October 7th. , For the trial, ... were randomly assigned to 4 grams of fish oil a ...
(Date:10/14/2014)... between 10 and 20 years to develop, providing ... intervention if detected early, which may be possible ... clinical researchers. , Dr Jeremy Humphris and ... Medical Research, analysed medical histories and tumour samples ... patients, operated on between 1994 and 20122. Roughly ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Early detection window when pancreatic cancer is in the family 2
... a long-distance race may do serious harm rather than ... much, according to a cardiologist at UT Southwestern Medical ... too much water during a race could put themselves ... a loss in the body's sodium content that can ...
... announced today the launch of the new GeneChip(R) ... with PreAnalytiX -- a joint venture between QIAGEN ... BD (Becton, Dickinson and Company). The new kits ... use with Affymetrix GeneChip technology and improve gene ...
... Earth history some 251 million years ago was preceded by ... by a delayed recovery that lasted for millions of years. ... a sharp decline in atmospheric oxygen levels was likely a ... very slow recovery. , Earth's land at the time was ...
Cached Biology News:Too much water may be as dangerous as too little during long-distance athletic events 2Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 2Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 3Scientists reveal the shape of a protein that helps retroviruses break into cells 2Scientists reveal the shape of a protein that helps retroviruses break into cells 3
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 400 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: